The acute haemodynamic effects of beta-blockade with propranolol and combined alpha-blockade and betablockade with labetalol were compared in a randomised study in 12 patients with coronary artery disease proved by angiography. Propranolol induced significantly greater depression of left ventricular function both at rest and during exercise than labetalol. This difference was probably attributable to the vasodilator activity of labetalol and the associated reduction in afterload offsetting the haemodynamic disadvantages of blockade of cardiac beta-adrenoceptors alone.
Introduction
Beta-blocking drugs are commonly used in coronary heart disease as symptomatic treatment for patients with angina pectorisl 2 and more recently have been advocated for the secondary prevention of myocardial infarction.3-7 By reducing heart rate and myocardial contractility8 they reduce myocardial oxygen consumption, but these benefits tend to be offset by a concomitant increase in left ventricular afterload.9 This stems from two sources. Firstly, blockade of myocardial beta,-receptors results in an increase in left ventricular volume.'0-"2 Secondly, blockade of vasodilator beta2-adrenoceptors in the peripheral circulation directly increases systemic vascular resistance and aortic impedance and this is further augmented by the reflex vasoconstriction resulting from the reduction in cardiac output.'3 Logically therefore, simultaneous reduction in afterload by vasodilatation could be expected to counter the depression of left ventricular pumping function resulting from beta-blockade alone. This hypothesis was tested by comparing the haemodynamic effects of equivalent beta-blocking doses of propranolol and labetalol, a drug which combines alpha-blocking and betablocking properties,'4 in patients with stable coronary heart disease.
Patients and methods
Twelve men aged 25-64 years, with symptomatic, electrocardiographic, and angiographic evidence of coronary heart disease were studied. All were normotensive and in sinus rhythm without clinical or radiographic signs of left ventricular failure. None had any clinical contraindications to the use of beta-blocking drugs and none were receiving drugs other than short-acting nitrates. Informed consent was given by all patients and the investigation agreed by the hospital ethics committee.
Patients were allocated at random to receive propranolol or labetalol (six in each group). A control period was started with four minutes' supine bicycle exercise at the predetermined symptom-limiting load (25-50 W); haemodynamic measurements were made during the final minute of exercise. When circulatory variables had restabilised, resting measurements were made for four minutes, after which propranolol or labetalol in equivalent beta-blocking doses'5 were infused intravenously over 20 minutes to give final cumulative doses of 16 mg for propranolol and 80 mg for labetalol respectively. Haemodynamic measurements were recorded during the four minutes immediately after completion of the intravenous infusion and bicycle exercise was then repeated at the same workload. Heart rate was measured from the electrocardiogram, systenmic arterial and pulmonary vascular pressures were externally transduced, and cardiac output was measured by computer integration of triplicate right-heart thermal-dilution curves. Pulmonary artery occluded pressure was taken as an index of left ventricular filling pressure, and systemic vascular resistance was calculated by conventional means. Probability of statistical significance of differences between data before and after taking drugs was tested by analysis of variance of repeated measurements.'617 325 Results There was comparable distribution between the two groups in terms of the severity of symptoms and extent of angiographic coronary artery disease. Left ventricular performance, however, in terms of the relation between left ventricular filling pressure and cardiac output was impaired to a greater extent in the patients allocated at random to receive labetalol than in those allocated to receive propranolol.
COMPARISON OF HAEMODYNAMIC EFFECTS OF PROPRANOLOL AND

LABETALOL
After propranolol the systemic blood pressure was unchanged at rest but significantly reduced during exercise compared with control values. Cardiac output and heart rate were reduced and pulmonary artery occluded pressure and systemic vascular resistance significantly increased, both at rest and during exercise (see table) .
After labetalol the systemic blood pressure and systemic vascular resistance were significantly reduced, both at rest and during exercise, compared with results before taking the drugs. Cardiac output at rest was increased and the response to exercise unchanged. Heart rate was unchanged compared with control values both at rest and during exercise. The pulmonary artery occluded pressure was unchanged at rest but increased during exercise after labetalol-(see table) .
Considering the rest and exercise relation between pulmonary artery occluded pressure and cardiac output, the left ventricular function curve was significantly shifted to the right after propranolol (p<0-01) but unchanged after labetalol, despite its greater initial depression in those taking labetalol (see figure). disease. Our results also support the validity of the haemodynamic argument on which this comparative study was based -namely, that concomitant dilatation of peripheral arterial resistance vessels affords a means of countering the depression of left ventricular function that is associated with beta-blockade alone. In our patients, the relation between the filling pressure of the left ventricle and its pumped output was largely unimpaired after combined alpha-blockade and beta-blockade with labetalol compared with the substantial depression that followed beta-blockade alone with propranolol. This contrasting effect of the two drugs on left ventricular pumping ability was most probably related to the reduction in pressure work induced by the vasodilator component of labetalol over and above its betablocking activity. These results are instructive, but they must be interpreted with caution. The results of acute intervention studies may not always reflect the quantitative effects of long-term treatment. Nevertheless, previous haemodynamic studies with these sympathomimetic blocking drugs have shown similar qualitative changes after their acute intravenous and chronic oral administration.20 It is also difficult to arrive at comparative physiological beta-blocking doses of these drugs when one possesses a vasodilator component. The doses we used, however, have been shown to possess about an equal degree of inhibition of isoprenaline tachycardia in man. 15 From the clinical viewpoint, there is no doubt that betablocking drugs offer a clinically effective treatment in many patients with exercise-induced angina pectoris. Our results suggest that the symptomatic efficacy of such treatment may be enhanced by the addition of alpha-blockade. The implication of these findings in patients undergoing long-term treatment with beta-blocking drugs for the secondary prevention of myocardial infarction is also of interest. Beta-blocking drugs aggravate the loss of myocardial reserve present in many of these patients. Our results suggest that in patients in whom beta-blocking drugs are indicated, concomitant vasodilator or alpha-blockade may afford a method of offsetting their haemodynamic disadvantages and enhancing their therapeutic activity.
